DOUGLAS DONALD ROSS

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi request reprint Management of common symptoms in terminally ill patients: Part I. Fatigue, anorexia, cachexia, nausea and vomiting
    D D Ross
    University of Maryland School of Medicine, Baltimore, USA
    Am Fam Physician 64:807-14. 2001
  2. doi request reprint Impact of breast cancer resistance protein on cancer treatment outcomes
    Douglas D Ross
    University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore VA Medical Center, Baltimore, MD, USA
    Methods Mol Biol 596:251-90. 2010
  3. ncbi request reprint Long-term evaluation of required coursework in palliative and end-of-life care for medical students
    Douglas D Ross
    Program in Experimental Therapeutics, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    J Palliat Med 8:962-74. 2005
  4. ncbi request reprint Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome
    Douglas D Ross
    University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Room 9 031 Lab Room 9 020 F, G, H, Bressler Research Building, 655 West Baltimore Street, Baltimore, MD 21201, USA
    Best Pract Res Clin Haematol 17:641-51. 2004
  5. ncbi request reprint Development of required postgraduate palliative care training for internal medicine residents and medical oncology fellows
    Douglas D Ross
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Cancer Educ 19:81-7. 2004
  6. ncbi request reprint Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance
    Douglas D Ross
    University of Maryland Greenebaum Cancer Center, Program in Experimental Therapeutics, University of Maryland School of Medicine, Departments of Internal Medicine and Pathology, Baltimore, MD 21201 USA
    Cancer Cell 6:105-7. 2004
  7. pmc Creative solution for implementation of experiential, competency-based palliative care training for internal medicine residents
    Douglas D Ross
    Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Cancer Educ 26:436-43. 2011
  8. ncbi request reprint Institutionalization of a palliative and end-of-life care educational program in a medical school curriculum
    D D Ross
    Departments of Medicine and Pathology, University of Maryland School of Medicine, Program in Experimental Therapeutics, University of Maryland Greenebaum Cancer Center, Baltimore Veterans Medical Center, Baltimore, Maryland, USA
    J Palliat Med 4:512-8. 2001
  9. ncbi request reprint Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis
    Takeo Nakanishi
    Greenebaum Cancer Center, University of Maryland School of Medicine, Room 9 045, Bressler Research Building, 655 W Baltimore St, Baltimore, MD 21201, USA
    Mol Pharmacol 64:1452-62. 2003
  10. ncbi request reprint Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
    L Austin Doyle
    The University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Oncogene 22:7340-58. 2003

Research Grants

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Management of common symptoms in terminally ill patients: Part I. Fatigue, anorexia, cachexia, nausea and vomiting
    D D Ross
    University of Maryland School of Medicine, Baltimore, USA
    Am Fam Physician 64:807-14. 2001
    ..For appropriate pharmacologic treatment, it is helpful to identify the pathophysiologic origin of nausea in each patient...
  2. doi request reprint Impact of breast cancer resistance protein on cancer treatment outcomes
    Douglas D Ross
    University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore VA Medical Center, Baltimore, MD, USA
    Methods Mol Biol 596:251-90. 2010
    ....
  3. ncbi request reprint Long-term evaluation of required coursework in palliative and end-of-life care for medical students
    Douglas D Ross
    Program in Experimental Therapeutics, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    J Palliat Med 8:962-74. 2005
    ....
  4. ncbi request reprint Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome
    Douglas D Ross
    University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Room 9 031 Lab Room 9 020 F, G, H, Bressler Research Building, 655 West Baltimore Street, Baltimore, MD 21201, USA
    Best Pract Res Clin Haematol 17:641-51. 2004
    ..These are all in phase I/II trials and show promise for future treatment...
  5. ncbi request reprint Development of required postgraduate palliative care training for internal medicine residents and medical oncology fellows
    Douglas D Ross
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Cancer Educ 19:81-7. 2004
    ..The need for better care for terminally ill patients led us to create an educational program to provide internal medicine residents and medical oncology fellows basic competency in palliative and end-of-life care...
  6. ncbi request reprint Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance
    Douglas D Ross
    University of Maryland Greenebaum Cancer Center, Program in Experimental Therapeutics, University of Maryland School of Medicine, Departments of Internal Medicine and Pathology, Baltimore, MD 21201 USA
    Cancer Cell 6:105-7. 2004
    ..Predictions of transporter involvement in drug effect were validated in selected cases, and furthermore produced novel leads relating ABC transporter expression and chemoresistance or chemosensitivity...
  7. pmc Creative solution for implementation of experiential, competency-based palliative care training for internal medicine residents
    Douglas D Ross
    Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Cancer Educ 26:436-43. 2011
    ..Resident and faculty evaluation of the training programs is favorable. Outcome-based measures are planned to evaluate long-term program effectiveness...
  8. ncbi request reprint Institutionalization of a palliative and end-of-life care educational program in a medical school curriculum
    D D Ross
    Departments of Medicine and Pathology, University of Maryland School of Medicine, Program in Experimental Therapeutics, University of Maryland Greenebaum Cancer Center, Baltimore Veterans Medical Center, Baltimore, Maryland, USA
    J Palliat Med 4:512-8. 2001
    ..In September 2000, the medical school's Clinical Years Committee officially designated the palliative and end-of-life care training modules a mandatory part of the curriculum, with satisfactory completion a requirement for graduation...
  9. ncbi request reprint Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis
    Takeo Nakanishi
    Greenebaum Cancer Center, University of Maryland School of Medicine, Room 9 045, Bressler Research Building, 655 W Baltimore St, Baltimore, MD 21201, USA
    Mol Pharmacol 64:1452-62. 2003
    ..We conclude that the X. laevis oocyte heterologous expression system is a valid and effective means of studying BCRP function and substrate specificity...
  10. ncbi request reprint Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
    L Austin Doyle
    The University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Oncogene 22:7340-58. 2003
    ..More prospective studies are needed, preferably combining BCRP protein or mRNA quantification with functional assays, in order to determine the contribution of BCRP to drug resistance in human cancers...
  11. ncbi request reprint A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia
    Kenneth S Bauer
    Greenebaum Cancer Center, University of Maryland School of Pharmacy, Allied Health Building Suite 540, 100 Penn Street, Baltimore, MD 21201, USA
    Leuk Res 29:263-71. 2005
    ..This combination including PSC-833 was well tolerated. Although a pharmacokinetic interaction might have been expected, PSC-833 did not significantly alter the disposition of idarubicin...
  12. ncbi request reprint Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage
    Takeo Nakanishi
    The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center Departments of Medicine and Microbiology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, USA
    Cancer Res 66:5007-11. 2006
    ..The exon 1 variation we observe suggests that alternative promoters of the BCRP gene exist...
  13. pmc A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells
    Leslie M Tompkins
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, United States
    Biochem Pharmacol 80:1754-61. 2010
    ....
  14. ncbi request reprint Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias
    Ken Shiozawa
    Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center, and Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Cancer Res 15:1698-707. 2009
    ..In this preclinical study, we evaluated combining cytosine arabinoside [1-beta-D-arabinofuranosylcytosine (ara-C)] and/or etoposide with vorinostat for use in the treatment of acute leukemias...
  15. ncbi request reprint Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL
    Tamer E Fandy
    School of Pharmacy, Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD 21201, USA
    Cancer Chemother Pharmacol 60:313-9. 2007
    ..We investigated the effect of flavopiridol pretreatment on TRAIL cytotoxicity and on the expression of FLIP(L) in different TRAIL-resistant cell lines, because FLIP expression is known to confer TRAIL-resistance...
  16. ncbi request reprint Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
    Takeo Nakanishi
    Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center UMGCC, Baltimore, 21201, USA
    Blood 108:678-84. 2006
    ..These studies show that BCRP causes measurable imatinib resistance, but this effect is attenuated by imatinib-mediated inhibition of BCR-ABL, which in turn downregulates overall BCRP levels posttranscriptionally via the PI3K-Akt pathway...
  17. ncbi request reprint Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 11:8403-12. 2005
    ....
  18. ncbi request reprint Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients
    Takeo Nakanishi
    Department of Medicine, Division of Hematology Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Clin Cancer Res 9:3320-8. 2003
    ..In vitro cell viability and apoptosis were examined after 24 h exposure to flavopiridol...
  19. doi request reprint Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors
    Xuetao Fan
    The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center, Departments of Medicine, Pathology and Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA
    Biochem Pharmacol 80:811-8. 2010
    ..Our findings indicate that LAT1 expression is increased in human ovarian cancer cell lines; LAT1 may be a target for combination therapy with anti-proliferative aminopeptidase inhibitors to combat ovarian cancer...
  20. pmc Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma
    Tamer E Fandy
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201 1180, USA
    Neoplasia 7:646-57. 2005
    ..Our study demonstrated the enhancing effects of HDAC inhibitors on apoptosis when combined with TRAIL and, for the first time, emphasized the role of AIF in mediating the cytotoxic effects of HDAC inhibitors...
  21. ncbi request reprint Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses
    Hong Bin Fang
    Division of Biostatistics, University of Maryland, Marlene and Stewart Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Stat Med 27:3071-83. 2008
    ..A study of two anticancer drugs, suberoylanilide hydroxamic acid (Vorinostat) and Etoposide applied sequentially against the cell line HL-60, is given to illustrate the proposed methods of experimental design and interaction analysis...
  22. ncbi request reprint Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells
    Dong I Lee
    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Arch Biochem Biophys 464:19-27. 2007
    ..Further, no cross-resistance occurs to other drugs. Thus, novel TG-specific resistance mechanisms are recruited by these cancer cells...
  23. ncbi request reprint Liquid chromatography method for the quantitation of the breast cancer resistance protein ABCG2 inhibitor fumitremorgin C and its chemical analogues in mouse plasma and tissues
    Tushar S Garimella
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 807:203-8. 2004
    ..Further, we found that a more potent analogue of FTC, Ko143, was able to be extracted and detected, with a maximal UV absorbance at 320 nm under the conditions reported...
  24. pmc The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells
    Yuexing Zhang
    Greenebaum Cancer Center and Departments of Pathology and Pharmacology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 102:9890-5. 2005
    ..These findings suggest that Ebp1 is a previously unrecognized therapeutic target for treatment of hormone refractory prostate cancer...
  25. ncbi request reprint Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial
    Judith E Karp
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 2120, USA
    Clin Cancer Res 9:307-15. 2003
    ..trigger apoptosis in fresh acute leukemia; and (b). recruit surviving leukemic cells to a proliferative state, thereby priming such cells for the S-phase-related cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C)...
  26. ncbi request reprint Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways
    Sharmila Shankar
    Department of Pharmaceutical Sciences, Molecular and Cellular Biology Program, University of Maryland, Baltimore, MD 21201 1180, USA
    Int J Mol Med 16:1125-38. 2005
    ..Thus, the combination of HDAC inhibitors and TRAIL can be used as a new therapeutic approach for the treatment of leukemia...

Research Grants2